|
|
| Biotechnologies Et Génétique > Etude de marché sectorielle |
| Monoclonal Antibody Therapies: Sector Analysis Tool |
|
|
|
|
€ 6 080,00 |
Editeur
: |
Datamonitor |
Langue
: |
Anglais |
Date de publication : |
Avril 2005 |
Taille du document : |
N/A |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
|
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
Strategies for Biogeneric Success
71 pages | Juin 2004 |
What will determine success? Development of biogeneric molecules for sale in the potentially highly lucrative US and Western European markets depends on the ability to answer three key questions |
1 500,00 €
|
| |
| |
03-026: The Market for Tissue Microarrays
134 pages | Juillet 2003 |
This report provides vital information on end-users’ scientific objectives, instrumentation for production and analysis of TMAs, outsourcing practices and preferred TMA suppliers |
640,00 €
|
| |
| |
Biochips IRCD
pages | Juillet 2001 |
The notion of a cheap and reliable computer chip look-alike that performs thousands of biological reactions is a very attractive one, because it miniaturizes, automates and accelerates otherwise cumbe |
1 200,00 €
|
| |
| |
03-071: Service & Support for Life Science Products
160 pages | Janvier 2004 |
This report examines the expectations of scientific customers as they relate to service and technical support from their suppliers |
1 280,00 €
|
| |
| |
The Biotechnology Industry in US & Europe
22 pages | Mai 2002 |
A new report by RocSearch, The Biotechnology Industry in US & Europe, gives an overview of the global biotechnology industry.
It emphasizes current and emerging technologies including monoclonal an |
500,00 €
|
| |
| |
Human Cloning: Economics and Ethics
36 pages | Mars 2003 |
Human cloning has moved from science-fiction novels, to science laboratories.
Pro-human cloning companies are racing to create the first cloned child, or make a breakthrough in stem cell research, |
850,00 €
|
| |
| |
Functional Proteomics and Emerging Bio-IT market
pages | Novembre 2002 |
The proteomic technique is not only limited to the study of one or few cellular products but also allows for qualitative and a quantitative measurement of several hundreds of proteins produced during |
250,00 €
|
| |
| |
04-001: Evaluating Online Advertising Opportunities @ Life Science Portals
176 pages | Février 2004 |
This report will help life science executives decide where to spend their advertising budget using the same criteria as their scientific customers, rather than assessing the value of a portal on the b |
1 120,00 €
|
| |
| |
03-010: The Market for Toxicogenomics Products & Services
193 pages | Avril 2003 |
This report provides a look at service providers, informatics products, microarrays and databases from the end-user's perspective |
640,00 €
|
| |
| |
Combinatorics
150 pages | Décembre 2000 |
Identified by The Economist (*) as the industry to watch for 1997 in the chemicals sector, Combinatorics (also known as combinatorial chemistry) is an emerging platform technology that uses test t |
1 400,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| Monoclonal Antibody Therapies: Sector Analysis Tool |
|
|
Introduction
The mAb Sector Analysis Tool presents the marketed and R&D portfolios, technology focus and product development strategies of over 100 key players in the mAbs market. In addition, you can to view, interrogate and tailor six-year sales forecasts for mAb products due to launch by 2010. This Sector Analysis Tool complements Monoclonal Antibody Therapies: Evolving into a $30 billion market (DMHC2069).
Reasons to Purchase
Access data on the leading mAb products, technologies and players in the global pharmaceutical market analyzing current and future trends
Compare players by global forecast therapy area sales and portfolio breakdown measures to identify winners and losers to 2010
Drill down to individual drug forecasts and descriptions, identifying the key drivers behind forecast performance over the next six years
|
|
|
PPLSEN
|
|
|
|
|
